Structural characteristics of articular cartilage proteoglycan in IgG induced experimental immune synovitis

CHARLES J MALEMUD,1 2 JUNG U YOO,3 VICTOR M GOLDBERG,3 AND THOMAS F KRESINA1

From the Departments of 1Medicine, 2Developmental Genetics and Anatomy, and 3Orthopaedics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA

SUMMARY The early changes (five weeks) in the structure of newly synthesised and endogenous articular cartilage sulphated proteoglycans were studied in lapine IgG induced experimental immune synovitis. Rabbits with immune synovitis (IS-IgG) were compared with animals with a developed hypersensitivity to IgG (I-IgG) and with non-treated normal weight matched controls. Medial and lateral femoral condyle and tibial plateau cartilage was pooled and radiolabelled for 24 h in vitro with 35SO4. The samples constituted tissue from regions underlying pannus and from pannus free sites. Cartilage from animals with IS-IgG showed a significantly diminished amount of newly synthesised and endogenous proteoglycan aggregate and an increased amount of hydrodynamically small proteoglycans. Newly synthesised (obtained by in vivo radiosulphate labelling) and endogenous proteoglycans showed a similar profile. The proteoglycan monomer fraction from animals with IS-IgG failed to form proteoglycan aggregates in the presence of excess hyaluronic acid. In the group with IS-IgG linear regression analysis showed a statistically significant relationship between the synovial pathology scores (but not cartilage pathology score) and diminished newly synthesised and endogenous proteoglycan aggregate.

Key word: rabbit.

The pathophysiological responses of articular cartilage accompanying synovial inflammation in rheumatoid arthritis remain unclear. Evidence has accumulated linking immunity to synovial joint extracellular matrix components in the pathogenesis of rheumatoid arthritis. For example, cell mediated immunity to genetically distinct collagens has been observed in classically defined rheumatoid arthritis,1-3 but a paucity of data exists with respect to proteoglycans. Recently, this laboratory has identified antibody to cartilage proteoglycan monomer in animals with experimentally induced immune synovitis (IS-IgG)4 and the presence of rheumatoid factor IgG and IgM antibodies in this animal model of arthritis (unpublished data).

Animal models of inflammatory arthritis have been studied to define more precisely the immune response to extracellular matrix components in arthritis. The presumption is that the components of cartilage extracellular matrix exist, under normal conditions, in a sequestered state. Once released from cartilage, and provided that they are in a form recognisable by immunocompetent cells, these components are capable of initiating cell mediated and humoral immune responses. It is important to note that the major portion of these extracellular matrix molecules comes from the already established structurally stable cartilage matrix. Thus a tenet of this hypothesis is that enhanced release of extracellular matrix components occurs as a consequence of local joint disturbances involving cell communications,5 6 monokine and lymphokine mediated activation, and synthesis of proteoglycanases and collagenase derived from synoviocytes and chondrocytes.7-11

The alterations in proteoglycan and collagen structure are not solely limited to areas of the cartilage-pannus interface in inflammatory arthritis as erosions are frequently seen in pannus free areas.
Articular cartilage proteoglycan in immune synovitis

as well. In addition, compensatory synthesis repair of proteoglycans and collagen by the affected joint must also be considered in this regard, since marked structural alterations due to disease would result in their inability to become an established component of the cartilage extracellular matrix.

The present investigation studied early changes in newly synthesised and endogenous proteoglycans in a well established animal model of rheumatoid arthritis, which involves hyperimmunisation of rabbits with autologous IgG before intra-articular injection of IgG. The studies have been conducted under defined short term explant culture conditions and compared with in vivo biosynthesis and alterations in the proteoglycan of articular cartilage.

Materials and methods

RABBITS

New Zealand White female virgin rabbits (2–3 kg) were obtained from the H and E rabbitry (Cleveland, OH).

ANTIGEN

Rabbit IgG was purchased from Miles Laboratories Inc. (Elkhart, IN).

INDUCTION OF SYNOVITIS

Antigen induced immune synovitis was produced by a modified method of Goldberg et al. Rabbits were primed subcutaneously (s.c.) with 4-0 mg homologous rabbit IgG emulsified in Freund’s complete adjuvant, boosted 1 week later with 2-0 mg of IgG (s.c.) and 2 days later skin tested for reactivity to IgG and PPD. Only responding rabbits were used for induction of immune synovitis. During the subsequent 4 weeks, each rabbit received 1 mg IgG solubilized in 0.3 ml saline, injected intra-articularly twice weekly into the left knee. Animals were killed after 5 weeks of intra-articular injection (IS-IgG). Some rabbits with a defined hypersensitivity to IgG were injected intraarticularly with saline (I-IgG). Weight matched non-treated animals served as a control group.

PATHOLOGY SCORING

A pathology score was derived by assigning equal weight to each of three parameters: cartilage, synovium and synovial fluid, as described previously. Where appropriate, bacterial cultures were established. All proved negative for bacterial growth.

EX VIVO SHORT TERM ORGAN CULTURE

Immediately after sacrifice the articular cartilage from the medial and lateral femoral condyle and tibial plateau was pooled, and briefly incubated with testicular hyaluronidase. Minces of articular cartilage were incubated in Dulbecco’s modified Eagle’s medium (sulphate free) (Gibco, Grand Island, NY) containing 10% (v/v) individually collected autologous rabbit sera as previously described. Na2SO4 (370 kBg/ml) (carrier free, ICN, Irvine, CA) was added for 24 h.

IN VIVO

Twenty four hours before sacrifice, four normal, three I-IgG, and four IS-IgG rabbits were injected with 35SO4 (27.8 MBq/kg) through the marginal ear vein.

PROTEOGLYCAN EXTRACTION

Articular cartilage minces were washed several times with saline. The tissue was extracted with 4 M guanidine hydrochloride/0-1 M sodium acetate buffer, pH 5.8, containing a mixture of proteinase inhibitors, and, in addition, phenylmethane sulphonyl fluoride (1 mM) for 24 h at 4°C with constant agitation. The extract was centrifuged and the supernatant dialysed exhaustively against double distilled deionized water (Ω=14) at 4°C for 48 h. The retained fraction was freeze dried.

PROTEOGLYCAN EXTRACTION EFFICIENCY

The pellet obtained by centrifugation of the cartilage extract was solubilised by digestion with papain followed by β elimination with dilute alkali. The incorporated radioactivity and carbazole reactivity as a measure of uronic acid content were assayed on digested dialysed material. Proteoglycan extraction efficiency was calculated from the total incorporated 35SO4 and uronic acid in the supernatant and the digested pellet.

PROTEOGLYCAN FRACTIONATION AND CHROMATOGRAPHIC ANALYSES

The 4 M guanidine hydrochloride (GuHCl) extract was processed according to the scheme shown in Fig. 1. Equilibrium centrifugation under associative conditions (A) was performed in CsCl with 0-5 M guanidine hydrochloride/0-1 M acetic buffer, pH 5.8. Under dissociative conditions (D) the buffer was 4 M guanidine hydrochloride/0-1 M sodium acetate, pH 5.8. Proteoglycan aggregate fraction (dAl) was subjected to reduction/alkylation and chromatographed on Sepharose CL-2B.

STATISTICAL ANALYSIS

The statistical significance between group means was obtained from the Student’s t test (p<0.05). A linear regression line was obtained by least squares.
Fig. 1  Preparation of proteoglycan from rabbit articular cartilage under associative and dissociative conditions and chromatographic analyses.

Results

PROTEOGLYCAN EXTRACTION
The extraction efficiency of newly synthesised and endogenous proteoglycan was measured in control, I-IgG, and IS-IgG rabbits killed at five weeks. The total uronic acid content of IS-IgG articular cartilage extracted with 4 M guanidine hydrochloride did not differ significantly from either normal or I-IgG animals (data not shown). The extraction efficiency of the newly synthesised proteoglycan from animals with IS-IgG was somewhat diminished (mean (SD); normal 89-7 (2-0)%; I-IgG, 85-7 (1-0); IS-IgG 79-2 (2-5); n=4), but the differences between the means did not reach statistical significance. Virtually identical amounts of endogenous proteoglycans as measured by uronic acid content were extracted from each group (normal 72-0 (11-5)%; I-IgG 75 (4-0); IS-IgG 71-5 (15-0).

DISTRIBUTION OF PROTEOGLYCAN IN ASSOCIATIVE CsCl DENSITY GRADIENTS
The percentage of incorporated $^{35}$SO$_4$ in the most dense dA1 fraction of the three groups studied was the same. The dA1 fraction comprised 69-2–75-7% of the newly synthesised proteoglycan in animals with IS-IgG and 76-7–78-8% in controls. The percentage of endogenous proteoglycans reaching equilibrium in the dA1 fraction was somewhat diminished in the IS-IgG group (55-9–65%) compared with the other groups (74-7–76-4%).

GEL FILTRATION CHROMATOGRAPHY OF dA1 FRACTIONS
The distribution of newly synthesised proteoglycan in the dA1 fraction in IS-IgG cartilage as measured by Sepharose CL-2B chromatography was different from that of either control group. There was a diminished amount of newly synthesised proteoglycan aggregate and an increase in the amount of newly synthesised hydrodynamically small proteoglycan subpopulation (fraction III) (Table 1). The endogenous proteoglycan also showed statistically
significant differences between IS-IgG and control groups (Table 1). In addition to reduced quantities of proteoglycan aggregate, IS-IgG fraction dA1 showed a shift to subpopulations of smaller hydrodynamic size.

Reduction and alkylation of the dA1 fraction showed no differences among the groups in the hydrodynamic size of the proteoglycan monomer (Fig. 2). Neither the newly synthesised nor the endogenous proteoglycan monomer in the dA1 fraction of IS-IgG cartilage was hydrodynamically smaller than either of the control groups.

IN VIVO EXPERIMENTS
We ascertained whether the changes in the distribution of proteoglycan in the dA1 fraction of IS-IgG rabbit cartilage measured in ex vivo explant culture occurred in vivo as well. The amount of newly synthesised proteoglycan aggregate found in IS-IgG cartilage was significantly diminished (Table 2). In addition, there was a marked increase in the hydrodynamically small proteoglycan subpopulation (fraction III). No changes were seen in fraction II. Interestingly, these alterations were not found in the dA1 fraction of cartilage derived from the contralateral knee of rabbits with IS-IgG (data not shown). This suggested that the change in elution profile of fraction dA1 was limited to the pathologically affected knee.

FORMATION OF PROTEOGLYCAN AGGREGATES
Proteoglycan monomer fractions (dD1) were prepared from pooled fraction II and fraction III after chromatography of dA1 fractions with Sepharose CL-2B. The contribution of the uronic acid from the exogenous hyaluronic acid was subtracted from the total carbazole reactivity to obtain the percentage of endogenous proteoglycan monomer that had formed proteoglycan aggregate. Approximately

Table 1 Distribution of newly synthesised and endogenous proteoglycan in fraction dA1 on Sepharose CL-2B

<table>
<thead>
<tr>
<th>Group</th>
<th>Fraction I (%)</th>
<th>Fraction II (%)</th>
<th>Fraction III (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal (n=6)</td>
<td>16.7 (9.6)</td>
<td>61.5 (14.5)</td>
<td>20.0 (13.7)</td>
</tr>
<tr>
<td>IS-IgG (n=9)</td>
<td>15.4 (8.5)</td>
<td>55.3 (16.7)</td>
<td>26.8 (25.7)</td>
</tr>
<tr>
<td>Uronic acid</td>
<td>4.4 (2.6)*</td>
<td>54.2 (12.1)</td>
<td>38.1 (10.8)*</td>
</tr>
</tbody>
</table>

Fraction dA1 was prepared from a 4 M guanidine hydrochloride extract of articular cartilage. An aliquot (0.5 ml) of the fraction was applied to a column of Sepharose CL-2B (4.4 cm x 113 cm) and eluted with 0.5 M sodium acetate buffer, pH 7. One millilitre fractions were collected. Column fractions corresponding to K, values of 0-0.17 (fraction I), 0.18-0.57 (fraction II), and 0.58-1.0 (fraction III) were pooled. Recovery of radioactivity and uronic acid was as previously published.

Values are mean (SD); n=number of individual animals.

*p<0.01; **p<0.05.

Fig. 2 Sepharose CL-2B chromatography of reduced and alkylated dA1 fractions. Fraction dA1 was chromatographed on Sepharose CL-2B and eluted with 0.5 M sodium acetate buffer, pH 7, after reduction and alkylation. The V(1)(K(w)=0) was obtained with bovine cartilage proteoglycan aggregate and the V(1)(K(w)=1) with Na2(SO4)2. The arrow indicates the peak elution fraction of endogenous hexuronic acid (K(w)=0.35).

Table 2 Distribution of newly synthesised and endogenous proteoglycans in fraction dA1 obtained after in vivo labelling with 35SO4

<table>
<thead>
<tr>
<th>Group</th>
<th>Distribution (%)</th>
<th>Fraction I</th>
<th>Fraction II</th>
<th>Fraction III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal (n=4)</td>
<td>35SO4 acid</td>
<td>22.1 (11.2)</td>
<td>35.1 (19.3)</td>
<td>37.9 (24.4)</td>
</tr>
<tr>
<td>IS-IgG (n=3)</td>
<td>Uronic acid</td>
<td>39.5 (14.5)</td>
<td>35.5 (13.5)</td>
<td>25.0 (6.5)</td>
</tr>
<tr>
<td>IS-IgG (n=4)</td>
<td>35SO4 acid</td>
<td>13.8 (6.2)</td>
<td>41.8 (22.6)</td>
<td>41.5 (28.3)</td>
</tr>
<tr>
<td>IS-IgG (n=4)</td>
<td>Uronic acid</td>
<td>24.0 (8.5)</td>
<td>43.0 (11.0)</td>
<td>33.0 (10.5)</td>
</tr>
</tbody>
</table>

Fraction dA1 was chromatographed on Sepharose CL-2B. Pooled fractions (see footnote to Table 1) were measured for radioactivity and carbazole reactivity. Values are mean (SD).

*p<0.05.
82% of fraction II and 65% of fraction III reached equilibrium in the most dense fraction (dD1) after centrifugation. There were no differences between the groups. The endogenous proteoglycan monomer in fraction II formed proteoglycan aggregates which were decreased in the IS-IgG group (Table 3). Virtually none of the newly synthesised proteoglycan in fractions II or III formed proteoglycan aggregates.

**CORRELATION OF GROSS PATHOLOGY AND ALTERATIONS IN PROTEOGLYCANS**

The average pathology score of the combined femoral and tibial cartilage of the affected side was 2.94 in agreement with previously reported data in this model. The tibial score (3.11) was somewhat higher than the femoral score (2.78). There was a significant relationship between the pathology scores of the femur and the tibia (r=0.85, p<0.01, n=9). The pathology scores of the synovium and synovial fluid were in agreement with previously reported data. The combined score was 2.44. In contrast, the pathology score of normal control animals was zero; those of I-IgG and that of the contralateral knee of the IS-IgG group animals had an average score of 1. The results of regression analysis showed that cartilage pathology scores did not reach a significant correlation with either the newly synthesised or endogenous proteoglycan aggregate (Figs 3A and B). In contrast, there was a statistically significant relationship between the diminution of proteoglycan aggregate and the pathology score of the synovium (Figs 3C and D).

**Discussion**

The destruction of articular cartilage and underlying subchondral bone is a hallmark of inflammatory arthritis. Depletion of cartilage extracellular matrix components occurs aggressively, mediated in part by enzymatic dissolution of proteoglycan and collagen. In chronic forms of synovitis, activators of chondrocyte proteinases secreted by inflammatory synovia are believed to have a central role in the final common pathway of joint damage.

---

![Fig. 3](http://ard.bmj.com/) Regression analysis determining the strength of correlation of pathology scores with newly synthesised and endogenous proteoglycan aggregate in fraction dA1. The linear regression line (○—○) was obtained by least squares analysis. (A) Cartilage score v endogenous proteoglycan aggregate; (B) cartilage score v newly synthesised proteoglycan aggregate; (C) synovium score (synovium + synovial fluid) v endogenous proteoglycan aggregate; (D) synovium score v newly synthesised proteoglycan aggregate.

---

**Table 3** Formation of proteoglycan aggregates

<table>
<thead>
<tr>
<th>Group</th>
<th>2B Fraction</th>
<th>Fraction I (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1-4</td>
</tr>
<tr>
<td>Normal</td>
<td>II 35SO4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Uronic acid</td>
<td>25-0</td>
</tr>
<tr>
<td></td>
<td>III 35SO4</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Uronic acid</td>
<td>10-0</td>
</tr>
<tr>
<td></td>
<td>II 35SO4</td>
<td>4-5</td>
</tr>
<tr>
<td></td>
<td>Uronic acid</td>
<td>19-0</td>
</tr>
<tr>
<td></td>
<td>III 35SO4</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Uronic acid</td>
<td>12-0</td>
</tr>
<tr>
<td>I-IgG</td>
<td>II 35SO4</td>
<td>1-1</td>
</tr>
<tr>
<td></td>
<td>Uronic acid</td>
<td>5-0</td>
</tr>
<tr>
<td></td>
<td>III 35SO4</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>Uronic acid</td>
<td>0-0</td>
</tr>
</tbody>
</table>

A proteoglycan monomer fraction (dD1) was generated from pooled eluates of fraction II and fraction III (see footnote to Table 1) by density gradient ultracentrifugation in CsCl in dissociative buffer (4 M guanidine hydrochloride). The dD1 fractions were dialysed and freeze dried. The freeze dried sample was dissolved in 0.5 M sodium acetate buffer, pH 7, and dialysed with umbilical cord hyaluronic acid against sodium acetate buffer at 4°C for 24 h. An aliquot of this sample was chromatographed on Sepharose CL-2B and the radioactivity and carbazole reactivity of pooled fraction I assayed. Bovine nasal proteoglycan aggregate (A1) was used to calculate the V₀ of the column. ND=not determined because radioactivity was at background levels (<15 cpm).
Compensatory synthesis of cartilage proteoglycans occurs in articular cartilage in response to trauma and enzymatic depletion of the pericellular matrix. Noteworthy is recent evidence that catabolism (interleukin 1) and proteolytic enzymes, such as elastase, not only enhance proteoglycan catabolism but also suppress proteoglycan synthesis.

The results of this investigation indicated that the structure of the existing proteoglycan was altered as expected. The newly synthesised proteoglycan, however, was also affected as characterised by a reduction in the amount of proteoglycan aggregated to hyaluronic acid, and by the increased synthesis of hydrodynamically small proteoglycans.

The amount of proteoglycan aggregate was significantly diminished in the affected IS-IgG cartilage. Interestingly, the differences obtained in this study between control and IS-IgG rabbits were similar to those reported by Oegema and Behrens, who compared normal rabbits with rabbits chronically administered hydrocortisone. They found that in control animals 17-1% of the hexuronic acid and 10-7% of the incorporated $^{35}$SO$_4$ was in the proteoglycan aggregate subpopulation; this was reduced to 6-3% and 5-4% in animals treated with hydrocortisone.

The finding that the proteoglycan monomer generated by reduction and alkylation of the proteoglycan aggregate fraction did not differ among the three groups was unexpected. Thus proteoglycan monomer in the IS-IgG group that interacted with cartilage hyaluronic acid appeared to be protected from multiple cleavages in the chondroitin sulphate attachment region of the proteoglycan monomer, a finding recently supported by the data of Campbell et al.

The amount of the hydrodynamically small proteoglycan subpopulation (fraction III) was significantly increased in IS-IgG cartilage. Its origins are unknown at present. It is conceivable that it represents, in part, a degradation product of fraction II. In that case its quantitative increase in IS-IgG may have resulted from either synovial or cartilage proteinases.

Alternatively, small chondroitin sulphate proteoglycans have been reported as endogenous subpopulations of hyaline cartilage and as a specific low molecular weight synthesis product of articular chondrocytes. The fact that 62% of fraction III reached equilibrium with the most dense CsCl density gradient fraction suggests that shortened or undersulphated glycosaminoglycan chains are not likely to be an important characteristic of the small hydrodynamic size of this proteoglycan subpopulation.

The pathology score of the synovium indicated that it could be reasonably used to predict the extent of damage to the endogenous proteoglycan aggregate. In that respect, synovial inflammation reported to occur after repeated intra-articular saline injections may have been responsible for the slight decrease in fraction I in I-IgG animals. The negative slope obtained when synovial pathology scores were correlated with newly synthesised proteoglycan aggregate (Fig. 3D) indicated that low pathology scores are associated with a statistically significant smaller amount of newly synthesised proteoglycan aggregate than would normally be predicted.

Finally, these results argue persuasively that the synovium has a major role in the proteoglycan changes in IS-IgG. The fact that altered patterns of newly synthesised proteoglycan could be measured ex vivo suggests that factors secreted by synovium and affecting proteoglycans may also be recovered from the rabbit sera.

Heightened release of proteoglycan or its fragments from the tissue under these conditions is presumably responsible for the raised antiproteoglycan antibody titres measured in the serum of animals with IS-IgG.

Supported by NIH grants, AG-02205, AM-20618, and AM-07505 and a grant from the Orthopaedic Research and Education Foundation.

References
10. Gowen M, Wood D D, Ihrig E J, Meats J E, Russell R G G. Stimulation by human interleukin-1 of cartilage breakdown and...
Structural characteristics of articular cartilage proteoglycan in IgG induced experimental immune synovitis.
C J Malemud, J U Yoo, V M Goldberg and T F Kresina

Ann Rheum Dis 1987 46: 520-526
doi: 10.1136/ard.46.7.520

Updated information and services can be found at:
http://ard.bmj.com/content/46/7/520

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/